Discovery Biology Unit provides validated discovery assays, including in vitro assays (HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling) and in vivo disease models in cardiovascular, CNS, respiratory, metabolic and infectious diseases. Founded in 2008, we have multiple function teams of ~500 scientists, including 11% PhD, 55% MSc, and led by 12 seasoned scientific leaders with an average of 15 years of R&D experience in the US, Canada, and UK.
WuXi Biology offers structural biology services with customized and integrated solutions to advance your discovery projects
in vitro Biology
WuXi Biology offers comprehensive assays services that cover all major therapeutic target classes to support the in vitro pharmacological characterization. Our in vitro biology services include HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling.
- High Content Platform
- High Throughput Screening
- In Vitro Assays for Diabetes and Other Metabolic Diseases
- Cancer Cell Panel & In Vitro Oncology Assays
- Radioactive Assays
- GPCR, Transporter, NHR
- Cellular Assays
- Kinase Assay
- Ion Channel
- Enzymes/Biochemical Assays
- In vitro Safety Pharmacology ProfilingToxicology
in vivo Pharmacology
WuXi Biology has established multiple in vivo animal models to evaluate preclinical drug candidates. Each disease model is designed to understand specific aspects of drug property and its mechanism of action.
Infectious Disease Unit
WuXi Biology provides a comprehensive infectious disease platform from assay setup to clinical trial support.
Oncology and Immuno-oncology Unit
Our innovative platform covers all research needs ranging from target discovery, in vitro and in vivo pharmacology, and translational research to clinical biomarker testing enabling drug discovery for cancer, autoimmune disease and rare genetic diseases (RGD).